ALK-Positive Anaplastic Large Cell Lymphoma

6 clinical trials · Condition

Record	Firm	Date
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857)	Huiqiang Huang	2021-03-31
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459)	Huiqiang Huang	2020-07-23
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470)	Huiqiang Huang	2020-04-24
Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL (NCT03707847)	Mingzhi Zhang	2018-10-01
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451)	BeiGene	2018-04-13

Every clearance here is in the API, with alerts when new ones post.